NHMRC Clinical Trials Centre: gynaecological cancer trials

NHMRC Clinical Trials Centre

USGOG

Cancer trials
	Support for cancer trials
Breast cancer
Gastrointestinal cancer
Germ-cell cancer
Gynaecological cancer
Lung cancer
Brain cancer
Other cancer trials

Trials > Cancer > Gynaecological cancer

Gynaecological cancer trials

Oncology associate program manager: Julie Martyn

Pending trials | Closed trials

Australia New Zealand Gynaecological Oncology Group

Trials open to recruitment

SCOTROC4: Prospective, multicentre, randomised trial of carboplatin flat dosing versus intrapatient dose escalation in first-line chemotherapy of ovarian, fallopian tube and primary peritoneal cancers

TRIPOD: Single-arm, phase II trial of intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers (ANZGOG 0601)

Scottish Gynaecological Cancer Trials Group, Australia New Zealand Gynaecological Oncology Group

Participants
Women with ovarian, fallopian tube or peritoneal carcinoma for whom platinum–taxane therapy is not suitable

Treatment
• 6 cycles carboplatin, fixed dose, or
• 6 cycles carboplatin with changes to dose depending on neutrophil count

Outcome measures
• disease progression

Funding
Scottish Gynaecological Cancer Trials Group and Australian state cancer councils.

Status
Open to recruitment

Recruitment target
150 in Australia and New Zealand

Australia New Zealand Gynaecological Oncology Group

Participants
Women with ovarian and related cancers

Treatment
Paclitaxel and cisplatin injected into the abdominal cavity

Outcome measures
• safety
• quality of life

Funding
NSW Cancer Council

Status
Open to recruitment

A NZGOG 0602: Phase II trial of adjuvant chemoradiation followed by chemotherapy for endometrial carcinoma

ICON 7: Randomized, two-arm, multicentre open-label phase III study of adding bevacizumab to standard chemotherapy in patients with epithelial ovarian cancer

Australia New Zealand Gynaecological Oncology Group

Participants
Women with a new diagnosis of endometrial carcinoma at high risk of relapse after potentiallly curable surgery

Treatment
• radiation therapy plus weekly low-dose carboplatin for 6 weeks, or
• low-dose carboplatin only

Funding
Bristol-Myers Squibb Australia

Status
Open to recruitment

Gynecologic Cancer Intergroup, Australia New Zealand Gynaecological Oncology Group

Participants
Women with epithelial ovarian cancer who have not received systemic antitumour therapy

Treatment
• carboplatin and paclitaxel followed by regular assessment, or
• carboplatin, paclitaxel and bevacizumab, followed by bevacizumab and regular assessment

Outcome measures
• disease progression

Funding
UK Medical Research Council

Status
Open to recruitment

Open trials | Pending trials | Closed trials | Back to top

Pending new trial

PORTEC 3: Randomised phase III trial comparing concurrent chemoradiation and adjuvant chemotherapy with pelvic radiation alone in high-risk and advanced-stage endometrial carcinoma

Dutch Cooperative Gynecologic Oncology Group, Endometrial Subgroup of the UK National Cancer Research Institute, Australia New Zealand Gynaecological Oncology Group

Participants
Women with with FIGO stage I or 2 endometrial adenocarcinoma with high-risk features or stage 3 endometrial carcinoma who meet the inclusion criteria

Recruitment target
150

Open trials | Pending trials | Closed trials | Back to top

Closed trials

CALYPSO: Multinational randomised phase III study comparing pegylated liposomal doxorubicin (Caelyx) and carboplatin versus paclitaxel and carboplatin in patients with epithelial ovarian cancer in late relapse

Prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer (GOG 199)

Gynaecological Cancer Intergroup study

Participants
Women whose disease has progressed after treatment

Treatment
• pegylated liposomal doxorubicin + carboplatin, or
• paclitaxel + carboplatin

Outcome measures
• disease-free survival

Funding

Status
Closed to recruitment: in follow-up

Recruitment
71

US Gynecologic Oncology Group, Australia New Zealand Gynaecological Oncology Group

Participants
Women aged over 30 years at risk of ovarian cancer

Treatment
• choice of preventive surgery (salpingo-oophorectomy), or
• ovarian cancer screening

Outcome measures
• survival
• quality of life

Recruitment
83

A phase III randomised trial of paclitaxel and carboplatin versus triplet or sequential doublet combinations in patients with epithelial ovarian or primary peritoneal carcinoma (GOG182)

Tarceva: A randomised, multicentre, phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line, platinum-based chemotherapy for high-risk stage I and stage II–IV ovarian epithelial, primary peritoneal or fallopian tube cancer (EORTC 55041)

US Gynecologic Oncology Group, Australia New Zealand Gynaecological Oncology Group

Participants
Women with advanced stage (stage III or IV) primary ovarian or peritoneal cancer

Outcome measures
• survival
• disease-free survival
• toxicity

Status
Closed

Recruitment
183

European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group, Australia New Zealand Gynaecological Oncology Group

Participants
Women with high-risk stage I or stages II–IV ovarian cancer which has not progressed after first-line platinum chemotherapy

Treatment
• erlotinib maintenance after chemotherapy
• observation alone after chemotherapy

Outcome measures
• progression-free survival

Status
Closed

Recruitment
42

Open trials | Pending trials | Closed trials | Back to top

add page content}